Title: Lewis Joe Stafford: Innovator in Cancer Diagnostics and Therapeutics
Introduction
Lewis Joe Stafford is a notable inventor based in the United States. He has made significant contributions to the field of cancer diagnostics and therapeutics. His work focuses on the development of antibodies that target specific cancer-related antigens.
Latest Patents
Lewis Joe Stafford holds a patent for "Npc1 Antibodies That Bind A Muc5ac Epitope." This invention relates to the NPC-1 antigen on the MUC5AC protein, as well as the 16C3 antigen on CEACAM5 and CEACAM6 proteins. Additionally, it addresses the 31.1 epitope on the A33 protein, which is differentially expressed in various cancers, including lung cancer, ovarian cancer, pancreatic cancer, breast cancer, and colon cancer. The patent outlines diagnostic and therapeutic usages of these antibodies, emphasizing their potential in cancer treatment.
Career Highlights
Lewis Joe Stafford is currently associated with Neogenix Oncology, Inc., where he continues to advance his research in oncology. His work is pivotal in developing innovative solutions for cancer diagnostics and therapies.
Collaborations
He collaborates with esteemed colleagues, including Xiulian Du and Janos Luka, to further enhance the impact of his research in the field of oncology.
Conclusion
Lewis Joe Stafford's contributions to cancer research through his innovative patents and collaborations highlight his commitment to improving diagnostic and therapeutic methods. His work is essential in the ongoing fight against cancer.